Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.64−0.27 (-2.27%)
Close on Nov 18, 2026Market cap $1.51BP/E –Yield –
Mesoblast price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Mesoblast's price to sales ratio was 14.7× on Nov 11, 2026, against 121.0× a year earlier. Over the last 5 years it ranged from 14.7× to 336.7×, with a median of 69.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 14.7× | −112.0 |
| 2025 | Dec 31, 2025 | 126.7× | −204.3 |
| 2024 | Dec 31, 2024 | 331.0× | +308.2 |
| 2023 | Dec 29, 2023 | 22.8× | −27.0 |
| 2022 | Dec 30, 2022 | 49.8× | −11.6 |
| 2021 | Dec 31, 2021 | 61.4× | +4.5 |
| 2020 | Dec 31, 2020 | 56.9× | +23.7 |
| 2019 | Dec 31, 2019 | 33.1× | +19.1 |
| 2018 | Dec 31, 2018 | 14.1× | −179.2 |
| 2017 | Dec 29, 2017 | 193.2× | +184.1 |
| 2016 | Dec 30, 2016 | 9.2× | – |
See a number that looks wrong?